论文部分内容阅读
目的观察第三代钙通道阻滞剂乐卡地平治疗轻中度高血压的疗效和安全性。方法选取130例轻中度高血压患者,服用乐卡地平10mg/d,4周后未达到治疗要求者,加量至20mg/d,再服用4周。分别测量患者基线、第4周和第8周静息状态下的收缩压、舒张压和心率,同期空腹检查患者的血红蛋白、血小板、总胆红素、谷丙转氨酶、血肌酐、空腹及餐后2h血糖、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、血钾和血钠。结果130例轻中度高血压患者,服用乐卡地平至第4周和第8周时,与基线相比,平均收缩压和舒张压由(156.4±11.2)/(98.6±7.6)mmHg分别下降到(142.8±12.4)/(85.4±8.2)mmHg和(140.6±10.8)/(83.2±9.1)mmHg,P<0.05(1mmHg=0.133kPa)。患者的心率在第4周和第8周与基线相比,其变化无统计学意义(P>0.05)。共有6例(4.61%)患者出现不良反应。治疗前后血红蛋白、血小板、总胆红素、谷丙转氨酶、血肌苷、空腹及餐后2h血糖、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白、血钾和血钠等指标变化无统计学意义(P>0.05)。结论乐卡地平的降压疗效肯定,有良好的耐受性。
Objective To observe the efficacy and safety of levodipine, the third generation calcium channel blocker, in the treatment of mild to moderate hypertension. Methods A total of 130 mild to moderate hypertensive patients were enrolled in this study. After taking lercanidipine 10 mg / d for 4 weeks, the patients who did not meet the treatment requirements were enrolled. The dosage was 20 mg / d and then 4 weeks. Systolic blood pressure, diastolic blood pressure and heart rate were measured at baseline, at week 4 and week 8, respectively. Hb level, platelet, total bilirubin, alanine aminotransferase, serum creatinine, fasting and postprandial 2h blood glucose, total cholesterol, triglycerides, high density lipoprotein, low density lipoprotein, serum potassium and serum sodium. Results In 130 mild to moderate hypertensive patients, mean systolic and diastolic blood pressure decreased from (156.4 ± 11.2) / (98.6 ± 7.6) mmHg to baseline at week 4 and week 8, respectively, compared with baseline To (142.8 ± 12.4) / (85.4 ± 8.2) mmHg and (140.6 ± 10.8) / (83.2 ± 9.1) mmHg respectively, P <0.05 for 1 mmHg = 0.133 kPa. The heart rate of patients at 4 weeks and 8 weeks compared with the baseline, the change was not statistically significant (P> 0.05). A total of 6 patients (4.61%) had adverse reactions. Before and after treatment of hemoglobin, platelets, total bilirubin, alanine aminotransferase, serum creatinine, fasting and 2h postprandial blood glucose, total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, serum potassium and serum sodium and other indicators No significant change (P> 0.05). Conclusions The antihypertensive efficacy of lercanidipine is definite and well tolerated.